Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Praxis Precision Medicines Inc (PRAX)

Praxis Precision Medicines Inc (PRAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 940,255
  • Shares Outstanding, K 17,108
  • Annual Sales, $ 2,450 K
  • Annual Income, $ -123,280 K
  • 60-Month Beta 2.74
  • Price/Sales 378.03
  • Price/Cash Flow N/A
  • Price/Book 4.03
Trade PRAX with:

Options Overview Details

View History
  • Implied Volatility 95.80% ( -9.03%)
  • Historical Volatility 64.48%
  • IV Percentile 6%
  • IV Rank 6.09%
  • IV High 1,099.88% on 11/21/23
  • IV Low 30.68% on 10/18/23
  • Put/Call Vol Ratio 0.94
  • Today's Volume 66
  • Volume Avg (30-Day) 699
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 9,627
  • Open Int (30-Day) 17,236

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -2.39
  • Number of Estimates 6
  • High Estimate -1.81
  • Low Estimate -3.24
  • Prior Year -7.35
  • Growth Rate Est. (year over year) +67.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.92 +54.74%
on 06/25/24
58.66 -2.61%
on 07/22/24
+15.43 (+37.00%)
since 06/21/24
3-Month
33.01 +73.07%
on 06/20/24
58.66 -2.61%
on 07/22/24
+9.35 (+19.57%)
since 04/22/24
52-Week
12.75 +348.08%
on 07/27/23
67.21 -15.00%
on 03/26/24
+40.93 (+252.65%)
since 07/21/23

Most Recent Stories

More News
Stocks Give Up Early Gains as Nvidia Weighs on Chip Stocks

The S&P 500 Index ($SPX ) (SPY ) Tuesday closed down -0.28%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.08%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.36%. Stock indexes...

$SPX : 5,564.41 (+1.08%)
SPY : 554.65 (+1.03%)
$DOWI : 40,415.44 (+0.32%)
DIA : 404.15 (+0.30%)
$IUXX : 19,822.87 (+1.54%)
QQQ : 482.32 (+1.49%)
ZNU24 : 110-240 (+0.03%)
UPS : 145.18 (unch)
IP : 46.49 (+1.68%)
MMM : 104.97 (+1.01%)
NVDA : 123.54 (+4.76%)
GFS : 56.24 (+1.33%)
Invitae's Real-World Ciitizen Data Utilized in Praxis Precision Medicines' PRAX-222 IND Filing

/PRNewswire/ -- Invitae (NYSE: NVTA) and Praxis Precision Medicines, Inc. (NASDAQ: PRAX), today announced that real-world clinical insights from Invitae's...

NVTA : 0.0195 (+2.63%)
IONS : 50.61 (+5.83%)
PRAX : 57.13 (+3.95%)
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2022 Financial Results

PRAX-944 Phase 2b Essential1 Study topline results expected in 4Q22; primary endpoint updated to efficacy PRAX-562 Phase 1 study completed, confirming...

PRAX : 57.13 (+3.95%)
Praxis Precision Medicines to Present at 2022 Wedbush PacGrow Healthcare Conference

BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic...

PRAX : 57.13 (+3.95%)
Praxis Precision Medicines Reports Negative Results from PRAX-114 Phase 2/3 Monotherapy Aria Study in Patients with Major Depressive Disorder

Aria Study did not achieve statistical significance on the primary endpoint Strategic realignment to focus resources on Movement Disorders and Epilepsy...

PRAX : 57.13 (+3.95%)
Praxis Precision Medicines Adds Global Business Expertise to Board of Directors with Appointment of Jill DeSimone

BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic...

PRAX : 57.13 (+3.95%)
Praxis Precision Medicines to Present at Upcoming Investor Conferences

BOSTON, May 11, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic...

PRAX : 57.13 (+3.95%)
Praxis Precision Medicines Reports Positive Topline Results from PRAX-944 Phase 2a Study in Essential Tremor Patients

PRAX-944 demonstrated clinically meaningful functional improvement in essential tremor patients in Part B of Phase 2a study Mean improvement at Day 42 was...

PRAX : 57.13 (+3.95%)
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2022 Financial Results

PRAX-944 demonstrated clinically meaningful functional improvement in essential tremor patients in Part B of Phase 2a study PRAX-114 Phase 2/3 monotherapy...

PRAX : 57.13 (+3.95%)
Praxis Precision Medicines to Provide Corporate Update and Report First Quarter 2022 Financial Results on Monday, May 9, 2022

BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic...

PRAX : 57.13 (+3.95%)

Business Summary

Praxis Precision Medicines Inc. is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance. Praxis Precision Medicines Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 63.15
2nd Resistance Point 60.90
1st Resistance Point 59.02
Last Price 57.13
1st Support Level 54.89
2nd Support Level 52.64
3rd Support Level 50.76

See More

52-Week High 67.21
Last Price 57.13
Fibonacci 61.8% 46.41
Fibonacci 50% 39.98
Fibonacci 38.2% 33.55
52-Week Low 12.75

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar